Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.

Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.

Item
http://www.wikidata.org/entity/Q43268826
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.Optimal use of vitamin D when treating osteoporosisRecommendations for evaluation and management of bone disease in HIV.Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" StudyAlendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.Osteoporosis in men: insights for the clinicianComparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis.The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral ReseDisability for daily living is a predictor for joint replacement in patients with end-stage knee osteoarthritis.Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids.Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study.Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
P2860

Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.

Item
http://www.wikidata.org/entity/Q43268826
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Minimum required vitamin D lev ...... eatment in osteoporotic women.
@en
Minimum required vitamin D lev ...... eatment in osteoporotic women.
@nl
type
label
Minimum required vitamin D lev ...... eatment in osteoporotic women.
@en
Minimum required vitamin D lev ...... eatment in osteoporotic women.
@nl
prefLabel
Minimum required vitamin D lev ...... eatment in osteoporotic women.
@en
Minimum required vitamin D lev ...... eatment in osteoporotic women.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Minimum required vitamin D lev ...... eatment in osteoporotic women.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698
P921